This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Antiretroviral chemotherapy in HIV infection

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There are six main categories of antiretroviral drugs used in HIV infection:

  • nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs):
    • AZT (zidovudine)
    • ddI (didanosine)
    • ddC (zalcitabine)
    • d4T (stavudine)
    • 3TC (lamivudine)
    • abacavir
  • non-nucleoside analogue inhibitors of reverse transcriptase (NNRTIs):
    • etravirine
    • delavirdine
    • nevirapine
    • efavirenz
  • integrase inhibitors
    • raltegravir (RAL)
    • elvitegravir (EVG)
  • protease inhibitors (PIs):
    • amprenavir (APV, Agenerase)
    • atazanavir (ATZ, Reyataz)
    • saquinavir
    • ritonavir
    • indinavir
    • nelfinavir
    • lopinavir
  • fusion inhibitors – prevents fusion of viral membrane with the cell membrane
    • enfuvirtide T-20 (1)
  • coreceptor antagonists

Some serious or unusual side effects of antiretroviral therapy are:

  • NRTI’s – hypersensitivity, lactic acidosis and hepatomagaly, bone marrow suppression, pancreatitis, peripheral neuropathy, lipoatrophy
  • NNRTI’s – hypersensitivity hepatic toxicity, psychiatric problems
  • PI’s – hepatic toxicity, hyperlipdaemia, lipodystrophy, type 2 diabetes, ureteric colic, nephrolithiasis (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.